A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter study of subjects with mild to moderate psoriasis. Subjects will apply
PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive
days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles,
scalp, facial and intertriginous sites). Biopsies of one target plaque will be collected at
baseline (at least 7 days prior to first study treatment on Day 1) and at Days 29 and 64,
with a 7-day interval between biopsy at Day 29 and commencement of application of application
of active PH-10 on Day 36. Study data from each subject will serve as an internal control
(i.e., assessment at baseline and at the end of application of PH-10 vehicle) for assessment
of clinical and cellular response to active investigational agent.